Modular Facility Proof-of-Concept for Multi-Modal Bioprocessing: an innovative solution

by Thomas Hauser and Jérome Dalin | November 29, 2022

Vaccines Webinar 1st December 2022

This webinar describes the collaboration of

Merck KGaA, Darmstadt, Germany
, and G-CON to develop a proof-of-concept facility design that enables multi-modal bioprocessing with greater flexibility and agility which facilitates tech transfer and future expansion. Details about the design, timelines, and cost repartition will be included.

In this presentation you will explore:

• How to develop a proof-of-concept facility design that supports multi-modal bioprocessing
• Details about the specific design, timelines, and costs
• How this modular facility approach can be leveraged for your specific requirements

Register here

Business Development Manager at G-CON

Thomas Hauser is Business Development Manager for G-CON Manufacturing within the EMEA region. He works to educate the market for offsite prefabricated and prequalified factory and clean-room solutions in a drive to bring forward the pharmaceutical facility of the future. He also supports companies in the life science segment, mainly for expansion strategies, strategic facility implementation, start-up support, and pharmaceutical packaging supply and technologies. Before 2020, Thomas worked in various leading global positions, dealing with the global life science Industry.

Senior Consultant - Bioprocessing Strategy Development at Merck KGaA, Darmstadt, Germany

Jerome Dalin holds a Msc/Engineering degree in Industrial manufacturing and Biological engineering. He started his career at Sanofi Pasteur 20 years ago in vaccine process development in France and then joined our company in 2013 to manage bioprocessing sales with vaccine project coordination at a global level. From 2021 to 2022, Jerome led strategic initiatives and supported go-to-market strategies with special focus on vaccine and traditional modalities. In his current role, he’s focusing its activities on Biopharma 4.0 strategy development.

Related Posts

Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management

This collection of insights, produced through a partnership between

Merck KGaA, Darmstadt, Germany
,[geot_filter region="north-america" country=""...


In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and...

Improved endotoxin removal using ecofriendly detergents for intensified plasmid capture

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with...

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to...

Post Pandemic: How a new era of supplier-vender collaboration is transforming Biopharma

Check out this article where

's Eva Schaefer, Director of Supply Robustness,...

Strengthening the CDMO-Sponsor Partnership with Improved Data Sharing and Collaboration

Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous...

Scroll to Top